Clinical Trials Browser

Phase 1 × Unknown × pembrolizumab × Clear all

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06344715 2024-04-03

Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

Phase 1 Unknown

78 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT05311618 2024-04-01

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Phase 1 Unknown

71 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05872867 2024-03-12

MK-3475-E90

Phase 1 Unknown

54 enrolled

GastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06307093 2024-03-12

Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms

Phase 1 Unknown

90 enrolled

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Lung Neoplasms, Melanoma, Neoplasms

NCT04224480 2024-01-19

Longitudinal Immune-phenotyping of HCC Following MK-3475

Phase 1 Unknown

8 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT04294576 2023-11-09

FIH

Phase 1 Unknown

92 enrolled

Other solid neoplasm

Locally Advanced/Metastatic Solid Tumors

NCT05296772 2023-09-06

Phase 1 First-in-human Study of JS014

Phase 1 Unknown

60 enrolled

Lymphoid

Lymphoma, Neoplasms, Neoplasms, Experimental

NCT05739006 2023-08-02

Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies

Phase 1 Unknown

131 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05232409 2023-04-20

Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer

Phase 1 Unknown

72 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05700955 2023-01-26

Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma

Phase 1 Unknown

30 enrolled

CNS

Glioblastoma

NCT04460456 2022-06-30

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Phase 1 Unknown

58 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03626922 2022-06-10

Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients

Phase 1 Unknown

33 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02675946 2022-01-26

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

Phase 1 Unknown

72 enrolled

Gastrointestinal

Gastrointestinal Neoplasms

NCT04859777 2021-09-16

A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Phase 1 Unknown

70 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT05008861 2021-08-17

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Phase 1 Unknown

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02824965 2021-07-07

Pembrolizumab + CVA21 in Advanced NSCLC

Phase 1 Unknown

11 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04866485 2021-04-29

A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

Phase 1 Unknown

66 enrolled

Other solid neoplasm

Solid Tumor

NCT03396497 2019-09-25

Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer

Phase 1 Unknown

17 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

MK-3475-E90

Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms

Longitudinal Immune-phenotyping of HCC Following MK-3475

FIH

Phase 1 First-in-human Study of JS014

Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies

Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer

Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Pembrolizumab + CVA21 in Advanced NSCLC

A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer